1887

Abstract

is an important bacterial cause of a variety of infections and is associated with high morbidity and mortality. Infections caused by this bacterium are becoming more difficult to treat due to increasing resistance to many of the available antibiotics. Ceftolozane–tazobactam and ceftazidime–avibactam are two new cephalosporin/β-lactamase inhibitor combination antimicrobials that have demonstrated excellent activity against several multi-drug-resistant pathogens, including multi-drug-resistant . Cases of infections with isolates of multi-drug-resistant that are resistant to both of these antimicrobials have rarely been reported. We report a case of mastoiditis caused by that was resistant to both ceftolozane–tazobactam and ceftazidime–avibactam.

Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000092
2020-01-20
2020-02-28
Loading full text...

Full text loading...

/deliver/fulltext/acmi/10.1099/acmi.0.000092/acmi000092.html?itemId=/content/journal/acmi/10.1099/acmi.0.000092&mimeType=html&fmt=ahah

References

  1. Peleg AY, Hooper DC. Hospital-Acquired infections due to gram-negative bacteria. N Engl J Med 2010;362:1804–1813 [CrossRef]
    [Google Scholar]
  2. Pang Z, Raudonis R, Glick BR, Lin T-J, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 2019;37:177–192 [CrossRef]
    [Google Scholar]
  3. van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis 2016;63:234–241 [CrossRef]
    [Google Scholar]
  4. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009;22:582–610 [CrossRef]
    [Google Scholar]
  5. Bush K, Bradford PA. β-Lactams and β-Lactamase Inhibitors: An Overview. Cold Spring Harb Perspect Med 2016;6:a025247 [CrossRef]
    [Google Scholar]
  6. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa. Hippokratia 2012;16:303–307
    [Google Scholar]
  7. Sorbera M, Chung E, CW H, Marzella N. Ceftolozane/tazobactam: a new option in the treatment of gram-negative infections. PT 2014;39:828–832
    [Google Scholar]
  8. Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 2017;61:e01964–16 [CrossRef]
    [Google Scholar]
  9. Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R et al. Comparison of antimicrobial activity between Ceftolozane-Tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Int J Infect Dis 2017;62:39–43 [CrossRef]
    [Google Scholar]
  10. Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016. Antimicrob Agents Chemother 2017;61: [CrossRef]
    [Google Scholar]
  11. MacVane SH, Pandey R, Steed LL, Kreiswirth BN, Chen L. Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation. Antimicrob Agents Chemother 2017;61:e01183–17 [CrossRef]
    [Google Scholar]
  12. Gangcuangco LM, Clark P, Stewart C, Miljkovic G, Saul ZK. Persistent bacteremia from Pseudomonas aeruginosa with In Vitro resistance to the novel antibiotics ceftolozane-tazobactam and ceftazidime-avibactam. Case Rep Infect Dis 2016;2016:1520404 [CrossRef]
    [Google Scholar]
  13. Wi YM, Greenwood-Quaintance KE, Schuetz AN, Ko KS, Peck KR et al. Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms. Antimicrob Agents Chemother 2018;62:e01970–17 [CrossRef]
    [Google Scholar]
  14. Nguyen L, Garcia J, Gruenberg K, MacDougall C. Multidrug-Resistant Pseudomonas infections: hard to treat. but hope on the horizon? Curr Infect Dis Rep 2018;20:23
    [Google Scholar]
  15. Papp-Wallace KM, Zeiser ET, Becka SA, Park S, Wilson BM et al. Ceftazidime-avibactam in combination with fosfomycin: a novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa. J Infect Dis 2019;220:666–676 [CrossRef]
    [Google Scholar]
  16. Clinical Laboratory Standards Insitute M100 Performance Standards for Antimicrobial Susceptibility Testing10, 29th Edition. 2018
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.0.000092
Loading
/content/journal/acmi/10.1099/acmi.0.000092
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error